News

Itepekimab Failure A Setback For Sanofi And Regeneron
Regeneron and Sanofi face setbacks as itepekimab stumbles in phase 3. Click here to read why I believe SNY and REGN stocks ...
Nasdaq3d
Regeneron and Sanofi Announce Mixed Results from Phase 3 AERIFY Trials for Itepekimab in COPD Patients
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. Regeneron Forward-Looking Statements and Use of Digital Media This press release includes forward-looking statements that involve risks and ...
Why Regeneron Pharmaceuticals, Inc. (REGN) Crashed Last Week
We recently published a list of These 10 Stocks Just Rocked The Market. In this article, we are going to take a look at where ...
Sanofi, Regeneron fall after late-stage data for COPD therapy
Sanofi (NASDAQ:SNY) and Regeneron (NASDAQ:REGN) traded sharply lower in the premarket on Friday after the companies announced ...
Nasdaq3d
Regeneron, Sanofi: COPD Drug Itepekimab Meets Primary Goal In 1 Phase 3 Trial, But Fails In Another
Regeneron and Sanofi jointly develop Itepekimab under a ... opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New ...
Sanofi (SNY)’s MenQuadfi Becomes First MenACWY Vaccine Approved for Ages 6 Weeks and Up
The U.S. FDA has approved an expanded indication for Sanofi (NASDAQ:SNY)’s quadrivalent meningococcal vaccine, MenQuadfi, now ...
Sanofi to buy Vigil Neuroscience in $470M deal (update)
Sanofi (NASDAQ:SNY) said Wednesday it agreed to acquire clinical-stage biotechnology company Vigil Neuroscience (NASDAQ:VIGL) ...
Nasdaq6d
Sanofi Buys DR-0201 Myeloid Cell Engager From Dren Bio
Sanofi acquired DR-0201 from a private clinical ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...
Press Release: Sanofi To Acquire Blueprint Medicines, Expanding Portfolio In Rare Immunological Disease And Adding Early-Stage Pipeline In Immunology
Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology <l ...
Sanofi granted FDA label expansion for MenQuadfi meningococcal shot for infants
The U.S. Food and Drug Administration (FDA) has approved Sanofi’s (NASDAQ:SNY) meningococcal vaccine MenQuadfi for infants as ...
Nasdaq12d
Sanofi to Acquire Vigil Neuroscience for Up to $10.00 per Share in Cash; Transaction Expected to Enhance Alzheimer’s Drug Development
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. About Vigil Neuroscience Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common ...